Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Maraviroc

Nature Reviews Drug Discovery volume 7, pages 15–16 (2008)Cite this article

Abstract

Maraviroc (Selzentry; Pfizer) is a small-molecule drug that inhibits HIV-1 entry by blocking the interaction between HIV-1 and the chemokine receptor CCR5 on host cells. It became the first drug in its class to be approved by the US FDA for the treatment of patients with CCR5-tropic HIV-1 in combination with other antiretroviral agents in August 2007, and it was approved in Europe (where its trade name is Celsentri) in September 2007.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Maraviroc.

References

  1. Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Disc. 6, 959–966 (2007).

    Article  CAS  Google Scholar 

  2. Tsibris, A. M. & Kuritzkes, D. R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58, 445–459 (2007).

    Article  CAS  Google Scholar 

  3. Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).

    Article  CAS  Google Scholar 

  4. Food and Drug Administration. FDA labelling information [online], (2007).

  5. Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Med. 11, 1170–1172 (2005).

    Article  Google Scholar 

  6. European Medicines Agency. European Public Assessment Report [online], (2007).

  7. Clumeck, N. et al. A multicenter, randomized, double-blind, comparative rial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogeneis, Treatment and Prevention, Sydney, Australia, July 22–25 [Abstract WESS104]. IAS2007.org web site[online], (2007).

  8. Reeves, J. D. et al. Enhancements to the Trofile HIV coreceptor tropism assay enable reliable detection of CXCR4-using subpopulations at less than 1%. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 [Abstract H-1026]. American Society of Microbiology web site[online], (2007)

  9. Wilkin, T. J. et al. Chemokine coreceptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin. Infect. Dis. 44, 591–595 (2007).

    Article  CAS  Google Scholar 

  10. Koot, M. et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681–688 (1993).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Daniel Kuritzkes is at Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02114, USA dkuritzkes@partners.org,

    Daniel Kuritzkes

  2. Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK skar@uk.imshealth.com,

    Santwana Kar

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Daniel Kuritzkes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santwana Kar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

D. K. is a consultant to Pfizer, Schering-Plough and Monogram, and receives research support from Schering-Plough and Human Genome Sciences.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuritzkes, D., Kar, S. & Kirkpatrick, P. Maraviroc. Nat Rev Drug Discov 7, 15–16 (2008). https://doi.org/10.1038/nrd2490

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2490

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing